GB9921954D0 - Formulations for parenteral use of estramustine phosphate with improved pharmacological properties - Google Patents

Formulations for parenteral use of estramustine phosphate with improved pharmacological properties

Info

Publication number
GB9921954D0
GB9921954D0 GBGB9921954.5A GB9921954A GB9921954D0 GB 9921954 D0 GB9921954 D0 GB 9921954D0 GB 9921954 A GB9921954 A GB 9921954A GB 9921954 D0 GB9921954 D0 GB 9921954D0
Authority
GB
United Kingdom
Prior art keywords
formulations
pharmacological properties
parenteral use
estramustine phosphate
improved pharmacological
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB9921954.5A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Italia SRL
Original Assignee
Pharmacia and Upjohn SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia and Upjohn SpA filed Critical Pharmacia and Upjohn SpA
Priority to GBGB9921954.5A priority Critical patent/GB9921954D0/en
Publication of GB9921954D0 publication Critical patent/GB9921954D0/en
Priority to AU68363/00A priority patent/AU777763B2/en
Priority to IL14840900A priority patent/IL148409A0/xx
Priority to HU0202621A priority patent/HUP0202621A2/hu
Priority to CNB008129525A priority patent/CN1177583C/zh
Priority to JP2001522973A priority patent/JP2003509355A/ja
Priority to EP00956409A priority patent/EP1212040A1/en
Priority to EA200200369A priority patent/EA005308B1/ru
Priority to CZ2002943A priority patent/CZ2002943A3/cs
Priority to PL00353954A priority patent/PL353954A1/xx
Priority to CA002385063A priority patent/CA2385063A1/en
Priority to KR1020027003498A priority patent/KR20020059405A/ko
Priority to SK345-2002A priority patent/SK3452002A3/sk
Priority to BR0014063-5A priority patent/BR0014063A/pt
Priority to PCT/EP2000/007679 priority patent/WO2001019338A1/en
Priority to NZ517631A priority patent/NZ517631A/en
Priority to MXPA02002859A priority patent/MXPA02002859A/es
Priority to ZA200201743A priority patent/ZA200201743B/en
Priority to NO20021306A priority patent/NO20021306L/no
Priority to HK02108529.1A priority patent/HK1047227A1/zh
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB9921954.5A 1999-09-16 1999-09-16 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties Ceased GB9921954D0 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
GBGB9921954.5A GB9921954D0 (en) 1999-09-16 1999-09-16 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
MXPA02002859A MXPA02002859A (es) 1999-09-16 2000-08-03 Formulaciones para uso parenteral del fosfato de estramustina con propiedades farmacologicas mejoradas.
CZ2002943A CZ2002943A3 (cs) 1999-09-16 2000-08-03 Přípravky pro parenterální pouľití estramustin-fosfátu se zlepąenými farmakologickými vlastnostmi
CA002385063A CA2385063A1 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
HU0202621A HUP0202621A2 (hu) 1999-09-16 2000-08-03 Javított farmakológiai tulajdonságokkal rendelkező, parenteralis felhasználásra szolgáló ösztramusztin-foszfát készítmények
CNB008129525A CN1177583C (zh) 1999-09-16 2000-08-03 具有改进药理学性质的非肠胃道使用的雌莫司汀磷酸盐制剂
JP2001522973A JP2003509355A (ja) 1999-09-16 2000-08-03 薬理学的特性が改善されたリン酸エストラムスチン塩の非経口的使用のための処方
EP00956409A EP1212040A1 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
EA200200369A EA005308B1 (ru) 1999-09-16 2000-08-03 Препараты эстрамустинфосфата для парентерального применения
AU68363/00A AU777763B2 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
PL00353954A PL353954A1 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
IL14840900A IL148409A0 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
KR1020027003498A KR20020059405A (ko) 1999-09-16 2000-08-03 약리학적 성질이 개선된 에스트라무스틴 포스페이트의비경구 투여용 제형
SK345-2002A SK3452002A3 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
BR0014063-5A BR0014063A (pt) 1999-09-16 2000-08-03 Formulações papa uso parenteral de fosfato de estramustina com propriedades farmacológicas melhoradas
PCT/EP2000/007679 WO2001019338A1 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
NZ517631A NZ517631A (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
ZA200201743A ZA200201743B (en) 1999-09-16 2002-03-01 Formulations for parenteral use of estramustine phosphate with pharmacological properties.
NO20021306A NO20021306L (no) 1999-09-16 2002-03-15 Formuleringer for parenteral bruk av estramustinfosfat med forbedrede formakologiske egenskaper
HK02108529.1A HK1047227A1 (zh) 1999-09-16 2002-11-26 具有改進藥理學性質的非腸胃道使用的雌莫司汀磷酸鹽製劑

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9921954.5A GB9921954D0 (en) 1999-09-16 1999-09-16 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties

Publications (1)

Publication Number Publication Date
GB9921954D0 true GB9921954D0 (en) 1999-11-17

Family

ID=10861066

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9921954.5A Ceased GB9921954D0 (en) 1999-09-16 1999-09-16 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties

Country Status (20)

Country Link
EP (1) EP1212040A1 (ja)
JP (1) JP2003509355A (ja)
KR (1) KR20020059405A (ja)
CN (1) CN1177583C (ja)
AU (1) AU777763B2 (ja)
BR (1) BR0014063A (ja)
CA (1) CA2385063A1 (ja)
CZ (1) CZ2002943A3 (ja)
EA (1) EA005308B1 (ja)
GB (1) GB9921954D0 (ja)
HK (1) HK1047227A1 (ja)
HU (1) HUP0202621A2 (ja)
IL (1) IL148409A0 (ja)
MX (1) MXPA02002859A (ja)
NO (1) NO20021306L (ja)
NZ (1) NZ517631A (ja)
PL (1) PL353954A1 (ja)
SK (1) SK3452002A3 (ja)
WO (1) WO2001019338A1 (ja)
ZA (1) ZA200201743B (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658913B2 (en) 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
EP2620023B1 (en) 2010-09-21 2018-02-28 Telefonaktiebolaget LM Ericsson (publ) Air-interface timing synchronization sharing
WO2019094819A2 (en) * 2017-11-09 2019-05-16 Abon Pharmaceuticals, Llc Intravenous delivery systems for chemotherapy drugs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59108800A (ja) * 1982-12-13 1984-06-23 Japan Atom Energy Res Inst 誘導ミサイル作用および制癌剤の徐放性機能をもつ微粒子
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
GB9419153D0 (en) * 1994-09-22 1994-11-09 Erba Carlo Spa Estramustine formulations with improved pharmaceutical properties
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same

Also Published As

Publication number Publication date
AU777763B2 (en) 2004-10-28
CN1374858A (zh) 2002-10-16
CN1177583C (zh) 2004-12-01
HUP0202621A2 (hu) 2002-12-28
WO2001019338A1 (en) 2001-03-22
EA200200369A1 (ru) 2002-08-29
EP1212040A1 (en) 2002-06-12
AU6836300A (en) 2001-04-17
SK3452002A3 (en) 2002-08-06
ZA200201743B (en) 2003-05-28
CZ2002943A3 (cs) 2002-08-14
JP2003509355A (ja) 2003-03-11
NO20021306D0 (no) 2002-03-15
KR20020059405A (ko) 2002-07-12
IL148409A0 (en) 2002-09-12
CA2385063A1 (en) 2001-03-22
MXPA02002859A (es) 2003-07-21
EA005308B1 (ru) 2004-12-30
NO20021306L (no) 2002-04-24
BR0014063A (pt) 2004-06-29
HK1047227A1 (zh) 2003-02-14
PL353954A1 (en) 2003-12-15
NZ517631A (en) 2004-01-30

Similar Documents

Publication Publication Date Title
GB9921954D0 (en) Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
PL352409A1 (en) Derivatives of 1-trifluorometyl-4-hydroxy-7-piperidinyl-aminomethylochromane
GB9921958D0 (en) Formulations for parenteral use of estramustine phosphate and sulfoalkylether-cyclodextrins
HUP0202645A3 (en) Fornulations for parenteral use of estramustine phosphate and albumin
GB9900215D0 (en) Structure of vehicles
HUP0203384A3 (en) Process for the preparation of ketimines
TW435837U (en) Structure improvement of connector
HUP0203382A3 (en) Process for the preparation of ketimines
TW395176U (en) Structure of designed article
TW411904U (en) Improvement of displacement structure for mold socket
TW437318U (en) Assembly structure of main decorative body for decorative article
GB9918779D0 (en) Formulations for parenteral use of estramustine phosphate and albumin
TW403237U (en) Improvement of socket structure
TW422240U (en) Knock set for anti-thieving lock
TW420132U (en) Improved structure of pivoting for box body
AU141959S (en) Set of vehicle bumperettes
TW414404U (en) Structure improvement of connector
TW367864U (en) Improvement for transmission structure of mini-stepper
TW374536U (en) Improved structure for the hanger of the earphone
TW424959U (en) Structure improvement of SMA connector
IL128359A0 (en) Methods for the preparation of erythromycin derivatives
TW430178U (en) Improved multi-hole socket structure
GB9916989D0 (en) Control of male fertility
TW400884U (en) Improvement of lock structure
AU2954000A (en) The pharmacological use of certain cystine derivatives

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)